Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
By R. Grant, J. Lama, P. Anderson, V. McMahan, A. Liu, Lorena Vargas, P. Goicochea, Martin Casapia, Juan V. Guanira-Carranza, María E Ramírez-Cardich and 25 more. New England Journal of Medicine, 2010
4,579 citations recorded by the source corpus.
BACKGROUND Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition. METHODS We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC–TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counseling, condoms, and management of sexually transmitted infections. RESULTS The study subjects were followed for 3324 person-years (median, 1.2 years; maximum, 2.8 years). Of these subjects, 10 were found to have been infected with HIV at enrollment, and 100 became infected during follow-up (36 in the FTC–TDF group and 64 in the placebo group), indicating a 44% reduction in the incidence of HIV (95% confidence interval, 15 to 63; P = 0.005). In the FTC–TDF group, the study drug was detected in 22 of 43 of seronegative subjects (51%) and in 3 of 34 HIV-infected subjects (9%) (P<0.001). Nausea was reported more frequently during the first 4 weeks in the FTC–TDF group than in the placebo group (P<0.001). The two groups had similar rates of serious adverse events (P = 0.57). CONCLUSIONS Oral FTC–TDF provided protection against the acquisition of HIV infection among the subjects. Detectable blood levels strongly correlated with the prophylactic effect. (Funded by the National Institutes of Health and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT00458393.)
Subfields: Emergency Medicine, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/7747e29e6be29c24c9db1f107e50e05690e4105f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- L. A. Palinkas
- Gregory A. Aarons
- Geoffrey Curran
- C. Hendricks Brown
- V. Fonner
- R. Gandhi
- N. Duan
- Sarah L Dalglish
Citations in the corpus
- An observational study of preexposure prophylaxis uptake, sexual practices, and HIV incidence among men and transgender women who have sex with men (2014, neutral): “In randomised placebo-controlled trials, 1,2 adherence to PrEP (assessed by detection of drugs in blood) was a strong correlate of efficacy.”
- On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. (2015, background): “In a couple with HIV-1–positive partner 19 (10) 13 (6)”
- Sexually Transmitted Diseases Treatment Guidelines, 2015 (2015, background): “Recommendations and Reports MMWR / June 5, 2015 / Vol. 64 / No. 3 3 In addition to obtaining a behavioral risk assessment, a comprehensive STD/HIV risk assessment should include STD screening, because STDs are biologic markers of risk, particularly for HIV acquisition and transmission among some MSM”
- Effectiveness and safety of oral HIV preexposure prophylaxis for all populations (2016, methodology): “Drug resistance Six trials measured and reported cases of TDF or FTC drug resistance, identified using standardized clinical genotypic laboratory assays [8,18,24,32,45,47].”
- Preexposure Prophylaxis for the Prevention of HIV (2018, methodology): “These factors include (1) a lack of established concentrations in blood associated with robust efficacy of TDF or FTC for the prevention of HIV acquisition in adults after exposure during penile-rectal or penile-vaginal intercourse(118) and (2) the limited but growing availability of clinical labora”
- An Overview of Research and Evaluation Designs for Dissemination and Implementation (2017, background): “, PrEP to prevent HIV infection) (51), and Policies (e.”
- Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women (2015, neutral): “(%)‡ 163 (3) 42 (4) 27 (3) 34 (3) 24 (2) 36 (4)”
- Estimating per-act HIV transmission risk: a systematic review (2014, background): “Factors that increase transmission risk are high viral load [69], genital ulcer disease [70], and acute and late-stage disease [70,71], whereas factors that decrease risk are use of antiretrovirals for treatment [72,73], pre-exposure prophylaxis [16,17,74], male condom use [18], and male”